November 9, 2022
Athira Pharma to Present at Stifel 2022 Healthcare Conference
November 7, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
October 17, 2022
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
September 6, 2022
Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
August 15, 2022
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
August 3, 2022
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022
August 2, 2022
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
July 25, 2022
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022
June 22, 2022
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
June 7, 2022
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
Displaying 21 - 30 of 104